Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Spastazoline is an inhibitor of spastin (IC50 = 99 nM for the human enzyme).1 It is selective for spastin over a panel of 64 kinases but does inhibit tropomyosin-related kinase A (TrkA) by 65% at 2 µM. Spastazoline (10 µM) increases the number of cells with intracellular bridges during cell division, indicating microtubule stabilization, in HeLa cells expressing the recombinant human M87 isoform of spastin that contains the alternatively spliced exon 4 (M87e4). It inhibits neurite outgrowth in primary mouse hippocampal neurons when used at concentrations of 1 and 5 µM. Spastazoline (20 mg/kg, i.p.) increases spinal cord injury-induced motor impairments in mice, but it does not affect motor function in sham mice.2 It also delays spinal cord inflammation resolution in the same mice.
WARNING This product is not for human or veterinary use.
1. Designing a chemical inhibitor for the AAA protein spastin using active site mutations. Nat. Chem. Biol. 15(5), 444-452 (2019).
2. Inhibition of spastin impairs motor function recovery after spinal cord injury. Brain Res. Bull. 205, 110806 (2023).